Catalent CEO John Chiminski

Catal­ent inks deal with Phath­om to make GI drug at re­cent­ly-ren­o­vat­ed Ken­tucky site

Sum­mer’s over, but New Jer­sey-based CD­MO Catal­ent had time to squeak in one last deal.

Catal­ent has signed an agree­ment to com­mer­cial­ly man­u­fac­ture Phath­om Phar­ma­ceu­ti­cals’ lead drug, vono­prazan, for the treat­ment of gas­troin­testi­nal dis­eases. If the drug is ap­proved by the FDA, Catal­ent will man­u­fac­ture and pack­age the drug at its large-scale oral sol­id dose site in Win­ches­ter, KY. Phath­om has the rights to de­vel­op and com­mer­cial­ize vono­prazan in the US, Eu­rope and Cana­da.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters